Q2 Earnings Crush Estimates; Inflection Validated, but Risks Linger

What happened

Omada Health’s Q2 2026 earnings of $0.15 per share crushed estimates and swung from a year-ago loss, signaling that revenue growth and operating leverage are accelerating ahead of expectations. The beat validates the bull-case trajectory of >25% revenue growth and adjusted EBITDA approaching breakeven, but the report lacked member growth and GLP‑1 attach details. Heavy reliance on Cigna-affiliate payments ($104.3M in 9M’25) and unresolved internal-control weaknesses remain key overhangs. The stock, still near $12, reflects lingering governance and concentration discounts despite the positive profit inflection. Next catalysts are sustained member growth above 40% and concrete GLP‑1 adoption metrics.

Implication

If Omada can sustain 25%+ revenue growth with positive adjusted EBITDA and demonstrate GLP‑1 attach rates, the stock could approach the $20 bull case; however, partner concentration and internal control remediation must progress to support a durable premium multiple.

Thesis delta

The Q2 2026 earnings beat shifts the thesis from pending catalyst verification to modestly higher conviction that profitability is inflecting ahead of schedule. This reduces reliance on the March 5 audited results as a binary event, but the core risks of Cigna dependence and weak controls cap the upgrade until those overhangs moderate.